R & D

Neoadjuvant Opdivo (nivolumab) Plus Chemotherapy Significantly Improves Event-Free Survival in Patients with Resectable Non-Small Cell Lung Cancer in Phase 3 CheckMate -816 Trial

 This material is intended to notify the press release issued on November 8 (local time) by Bristol Myers Squibb, our license partner for Opdivo.
 Please click for the original press release.